Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Two recruiting experts discuss the main areas where biopharma employers and candidates don’t match up, from how the hiring process runs to what companies can truly pay new employees.
Original title: “The great disconnect: 4 ways companies, job candidates misalign”
Biopharmas developing CAR T therapies for autoimmune indications face major barriers to maximizing the market. Advances in the provider ecosystem and clinical infrastructure, as well as access and education, will be key to launching at scale.
Original title: “CAR Ts will only treat autoimmune diseases if we can scale delivery”
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $750,000 for Federal Fiscal Year 2026 funding to Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), subject to the availability of funds. The award supports activities to improve HIV care and treatment for children and eliminate mother-to-child HIV transmission faster, working with faith-based organizations (FBOs), faith-affiliated health f
Original title: “Notice of Award of a Single Source Cooperative Agreement To Fund Elizabeth Glaser Pediatric AIDS Foundation”
Vitruvias Therapeutics has “ceased operations” after voluntarily recalling a batch recall of generic thyroid tablets due to possible superpotency that could cause a range of adverse events.
Original title: “Vitruvias vanishes amid thyroid tablets recall over potential ‘superpotency’ concerns”
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.
Original title: “Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal”
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
Original title: “Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial”
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
Original title: “BMS ends Cellares pact over cell therapy production problems, triggering layoffs”
At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.
Original title: “Biohaven could get up to $795M in epilepsy alliance with SK Bio”
The talent pool not keeping pace with increased outsourcing demand is just one reason CDMOs have trouble filling roles, according to a search expert. He also told BioSpace who is most in demand and how candidates can stand out from the competition.
Original title: “CDMO hiring tough as demand for specialized talent outpaces supply”
Sovereign capital, guaranteed offtake, and localization mandates are reshaping how biotech deals get structured in the Gulf, ahead of the Riyadh Global Medical Biotechnology Summit (RGMBS) 2026, 14 to 16 September, where 59 agreements have been signed across three editions.
Original title: “Inside the Gulf biotech deal model, ahead of RGMBS 2026 in Riyadh”
Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
Original title: “Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test”
Haisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The new company will take on one of Haisco’s core immunology assets.
Original title: “China’s Haisco forms immunology biotech with up to $1.5B from American VCs”
After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur a rebound, some say.
Original title: “Will a ‘reset’ reignite investment in women’s health startups?”
Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told BioSpace.
Original title: “Lilly takes oral obesity race abroad with UK launch of Foundayo”